Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors

Ovarian cancer (OC) is the major cause of gynecological cancer-related deaths in Western countries[1]. Its relative low incidence and the absence of screening programs, represent major limitations to early disease detection[2]. As a result, OC is usually diagnosed at late stage with unfavorable impact on the outcome. Cytoreductive surgery, aimed to remove all the macroscopic implants from the abdomen and the pelvis, represents the only curative treatment option and is the therapeutic mainstay in early and advanced OC.

Source: Cancer Treatment Reviews - September 29, 2021 Category: Cancer & Oncology Authors: M. Bartoletti, L. Musacchio, G. Giannone, V. Tuninetti, A. Bergamini, G. Scambia, D. Lorusso, G. Valabrega, G. Mangili, F. Puglisi, S. Pignata Source Type: research